California Jury Awards $40 Million in Johnson & Johnson Talc Cancer Lawsuit 
Apple App Store Injunction Largely Upheld as Appeals Court Rules on Epic Games Case 
SoftBank Eyes Switch Inc as It Pushes Deeper Into AI Data Center Expansion 
ANZ Faces Legal Battle as Former CEO Shayne Elliott Sues Over A$13.5 Million Bonus Dispute 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
SpaceX Begins IPO Preparations as Wall Street Banks Line Up for Advisory Roles 
Nvidia Develops New Location-Verification Technology for AI Chips 
Westpac Director Peter Nash Avoids Major Investor Backlash Amid ASX Scrutiny 
SpaceX Insider Share Sale Values Company Near $800 Billion Amid IPO Speculation 
Intel’s Testing of China-Linked Chipmaking Tools Raises U.S. National Security Concerns 
Air Force One Delivery Delayed to 2028 as Boeing Faces Rising Costs 
Woolworths Faces Fresh Class Action Over Alleged Underpayments, Shares Slide 
United Airlines Tokyo-Bound Flight Returns to Dulles After Engine Failure 
JD.com Pledges 22 Billion Yuan Housing Support for Couriers as China’s Instant Retail Competition Heats Up 
United Airlines Flight to Tokyo Returns to Dulles After Engine Failure During Takeoff 
Korea Zinc Plans $6.78 Billion U.S. Smelter Investment With Government Partnership 
Orion Group purchased a controlling stake in LegoChem Biosciences, a South Korean research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines. The confectionery company is acquiring a 25.7% stake worth KRW550 billion or around $418 million.
With the size of its acquisition, the Orion Group has now become the largest shareholder of LegoChem Biosciences. The firm made the deal as it seeks to broaden its business and enter into new drug development business beyond antibody-drug conjugate platform technology, as per the Korea Joongang Daily.
What is Included in the Agreement
Pan Orion Corporation, the Hong Kong-headquartered subsidiary of the Orion Group, led the acquisition deal. Based on the reports, the agreement includes a combination of share purchases and rights offerings.
Moreover, it was stated in the electronic disclosure of the Financial Supervisory Service that Orion will buy 7.96 million units of new stakes at KRW59,000 per share. In addition, it will also purchase 1.4 million existing shares at the base rate of 56,186 per share. Orion is scheduled to settle the payment for the acquisition on March 29.
Orion's Venture Into Biotech Business
The Korea Economic Daily reported that this buyout deal not only marks the Orion Group's deeper venture into the biotech industry but is also expected to help the company in achieving its goal of giving a boost to LegoChem Biosciences by providing the needed financial push for clinical development and encouraging new technology research.
Once the deal is completed, Orion will be the largest shareholder in LegoChem Biosciences. Currently, the company's chief executive officer, Kim Yong Zu, holds the biggest share, and after the acquisition, he will still retain some of his shares and keep his CEO position. LegoChem is also set to become one of the confectionery giant's affiliates.
Photo by: Orion Website
